Literature DB >> 25896805

Ibuprofen attenuates cardiac fibrosis in streptozotocin-induced diabetic rats.

Weili Qiao1, Cheng Wang, Bing Chen, Fan Zhang, Yaowu Liu, Qian Lu, Hao Guo, Changdong Yan, Hong Sun, Gang Hu, Xiaoxing Yin.   

Abstract

OBJECTIVE: To investigate the effects of ibuprofen on cardiac fibrosis in a rat model of type 1 diabetes.
METHODS: The diabetic model was established by injecting streptozotocin into the rats. Then, ibuprofen or pioglitazone was given by gavage for 8 weeks. The cardiac fibrosis was assessed, and the major components of the renin-angiotensin system, the transforming growth factor β1 (TGF-β1) and the mammalian target of rapamycin (mTOR), were evaluated by histopathological, immunohistochemical, Western blot analysis or ELISA assay.
RESULTS: Obvious cardiac fibrosis was detected in the diabetic group and was alleviated by ibuprofen treatment. Angiotensin-converting enzyme (ACE), angiotensin (Ang) II and AngII type 1 receptor (AT1-R) levels were higher, and ACE2, Ang(1-7) and Mas receptor (Mas-R) were lower in the diabetic group. The ratio of ACE to ACE2 was raised in the diabetic group. All these changes were ameliorated by ibuprofen. TGF-β1 and mTOR were raised in the hearts of the diabetic group and were attenuated by ibuprofen treatment. There was no significant difference between the ibuprofen and the pioglitazone groups.
CONCLUSION: Ibuprofen could ameliorate the cardiac fibrosis in diabetic rats by reduction of the ACE/AngII/AT1-R axis and enhancement of the ACE2/Ang(1-7)/Mas-R axis, leading to a decrease in TGF-β1 and mTOR.
© 2015 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25896805     DOI: 10.1159/000375362

Source DB:  PubMed          Journal:  Cardiology        ISSN: 0008-6312            Impact factor:   1.869


  55 in total

1.  Explosive drug information in the time of COVID-19.

Authors:  Martin Schulz; Pia M Schumacher; Juliana Schneider; André Said; Ulrich Laufs
Journal:  Can Pharm J (Ott)       Date:  2021-06-16

Review 2.  Decrypting the cellular and molecular intricacies associated with COVID-19-induced chronic pain.

Authors:  Mousmi Rani; Ankit Uniyal; Vinod Tiwari
Journal:  Metab Brain Dis       Date:  2022-07-18       Impact factor: 3.655

Review 3.  Neuroinflammation in Parkinson's Disease - Putative Pathomechanisms and Targets for Disease-Modification.

Authors:  Alexander Grotemeyer; Rhonda Leah McFleder; Jingjing Wu; Jörg Wischhusen; Chi Wang Ip
Journal:  Front Immunol       Date:  2022-05-18       Impact factor: 8.786

4.  Pharmacological approaches to the treatment of COVID-19 patients.

Authors:  Lawrence C Sowers; Lucas S Blanton; Scott C Weaver; Randall J Urban; Charles P Mouton
Journal:  J Transl Sci       Date:  2020-04-17

5.  Nonsteroidal Antiinflammatory Drugs and Susceptibility to COVID-19.

Authors:  Joht Singh Chandan; Dawit Tefra Zemedikun; Rasiah Thayakaran; Nathan Byne; Samir Dhalla; Dionisio Acosta-Mena; Krishna M Gokhale; Tom Thomas; Christopher Sainsbury; Anuradhaa Subramanian; Jennifer Cooper; Astha Anand; Kelvin O Okoth; Jingya Wang; Nicola J Adderley; Thomas Taverner; Alastair K Denniston; Janet Lord; G Neil Thomas; Christopher D Buckley; Karim Raza; Neeraj Bhala; Krishnarajah Nirantharakumar; Shamil Haroon
Journal:  Arthritis Rheumatol       Date:  2021-05       Impact factor: 10.995

Review 6.  Management of Osteoarthritis During the COVID-19 Pandemic.

Authors:  Enrico Ragni; Laura Mangiavini; Marco Viganò; Anna Teresa Brini; Giuseppe Michele Peretti; Giuseppe Banfi; Laura de Girolamo
Journal:  Clin Pharmacol Ther       Date:  2020-06-22       Impact factor: 6.903

Review 7.  Non-steroidal anti-inflammatory drugs, pharmacology, and COVID-19 infection.

Authors:  Joëlle Micallef; Thomas Soeiro; Annie-Pierre Jonville-Béra
Journal:  Therapie       Date:  2020-05-07       Impact factor: 2.070

8.  The Impact of the COVID-19 "Infodemic" on Drug-Utilization Behaviors: Implications for Pharmacovigilance.

Authors:  Marco Tuccori; Irma Convertino; Sara Ferraro; Emiliano Cappello; Giulia Valdiserra; Daniele Focosi; Corrado Blandizzi
Journal:  Drug Saf       Date:  2020-08       Impact factor: 5.228

9.  No current evidence supporting risk of using Ibuprofen in patients with COVID-19.

Authors:  Paulo Ricardo Martins-Filho; Edmundo Marques do Nascimento-Júnior; Victor Santana Santos
Journal:  Int J Clin Pract       Date:  2020-10       Impact factor: 3.149

10.  Drug Repurposing for the Treatment of COVID-19: A Knowledge Graph Approach.

Authors:  Vincent K C Yan; Xiaodong Li; Xuxiao Ye; Min Ou; Ruibang Luo; Qingpeng Zhang; Bo Tang; Benjamin J Cowling; Ivan Hung; Chung Wah Siu; Ian C K Wong; Reynold C K Cheng; Esther W Chan
Journal:  Adv Ther (Weinh)       Date:  2021-05-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.